TRACK & TRACE, CODING, MARKING, VISION AND CONTROL
EXCELLENCE IN PHARMACEUTICAL PACKAGING
ISSUE DATE: 05 May 2011
TRAVTEC SYSTEMS EASE
CODING COMPLIANCE AT ASTRAZENECA
the installation of 15 Travtec systems to date at its Macclesfield site,
AstraZeneca is taking the lead in the development of effective technology
solutions to meet point of use authentication for national and international
legislation, both now and in the future. The
Travtec systems at the Macclesfield site ensure consistent quality coding of all
the necessary data.
has worked closely with AstraZeneca to install seven of its Pharmacarton Lite
coding stations, seven Print Conveyors and a manually-fed system, all of which
incorporate the Wolke m600 thermal inkjet coder, into existing lines.
The driving force behind the selection
of the Travtec systems has been anti-counterfeit regulations introduced into the
Turkish market, and latterly French CIP13 coding requirements, both of which
have necessitated the inclusion of 2D Datamatrix codes onto packs.
However, the European Parliament’s recently approved Falsified
Medicines Directive and other moves to co-ordinate a standardised Track &
Trace system for international markets have underlined the appropriateness of
this move. The Travtec systems have
the flexibility to be adapted for different coding requirements and can also be
upgraded to cope with serialisation.
Travtec option was adopted after a thorough evaluation of all available
equipment by AstraZeneca which concluded that thermal inkjet was the best and
most responsive technology for 2D Datamatrix requirements.
At the same time, the company recognised that consistent coding could
only be achieved with a reliable and effective pack handling system that would
present each pack in the correct way. It
was also important that any coding system was able to integrate easily with the
company’s existing Systech vision equipment.
was able to satisfy all these criteria,” explains John Currie, Project Manager
for UK Operations at AstraZeneca. “The
Pharmacarton system in particular is what holds the entire coding and inspection
system together and ensures all the other elements work effectively.”
Pharmacarton Lite has been designed to be easily integrated into existing
packaging lines without extension. It
provides total control of the carton during the print and vision process to
ensure the accurate and high quality printing of high density barcodes and 2D
codes to ECC200/GS1 standards. It
combines a precision multi-belt conveyor with a synchronised top hold down belt
and incorporates the Wolke m600 Advanced high resolution ink jet printer and an
OCR/OCV optical character verification system.
A fail-to-safety reject unit with pack confirmation further guarantees
the authenticity of each coded pack and helps to maintain line speeds.
m600 is able to print in real time. Data
can be inputted from a remote server through the built–in Ethernet port. The
user-friendly printer’s advanced HP technology and water-based inks deliver
clean and maintenance-free coding onto a wide range of substrates, producing
characters and bar codes up to 600 dpi, which is a particular advantage for the
successful production of 2D Datamatrix codes.
data makes set up easy and eliminates any potential for operator error.
The Pharmacartons at AstraZeneca are running at speeds of up to 200
cartons per minute.
says that the flexibility of the Pharmacarton has enabled it to be easily
retrofitted to existing lines in different places, according to individual line
equipment across the lines also means that operators can easily be moved to
a coding perspective this is one of the most challenging projects we have
undertaken, but working with Travtec has made the process as painless as
possible,” concludes John Currie.
of these 15 systems were installed in just nine months.
Inevitably commercial considerations meant some decisions and changes
were left to the last minute, but Travtec was totally flexible and fully
responsive to our needs, including making enhancements in line with our
fully understands the pharmaceutical market and this has contributed to a
thoroughly professional and successful working partnership.”
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com